PR Newswire
PALO ALTO, Calif.
,
June 3, 2022
/PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that
David Cory
, President and CEO, will present a company overview at the Jefferies Global Healthcare Conference on
Wednesday, June 8, 2022
at
9:00 AM ET
in
New York City
. The Company will also host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the Investors section of the Eiger BioPharmaceuticals website at
www.eigerbio.com
. A replay of the presentation will be available on the website for at least 90 days.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and reported positive results from
TOGETHER,
a Phase 3 investigator-initiated study.
All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for both congenital hyperinsulinism and post-bariatric hypoglycemia.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]
Media:
Sarah Mathieson
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:
https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-301560720.html
SOURCE Eiger BioPharmaceuticals, Inc.
